EFFICACY AND SAFETY OF USTEKINUMAB IN ASIAN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: A SUBPOPULATION ANALYSIS OF UNITI/IM-UNITI LONG-TERM EXTENSION THROUGH 5 YEARS
Toshifumi Hibi 1
Byong Duk Ye 2
Christopher Gasink 3
Yuya Imai 4
Carine Saadoun 5
Jianmin Zhuo 6
Shiho Kawamura 5
1 Kitasato University, Tokyo, Japan
2 Asan Medical Center, Seoul, Korea (Republic of)
3 Janssen Scientific Affairs, LLC, Horsham, United States
4 Janssen Pharmaceutical K.K., Tokyo, Japan
5 Janssen Pharmaceuticals Asia Pacific, Singapore, Singapore
6 Janssen China Research & Development, Shanghai
Session
IBD (Posters)
Conference
UEG Week 2022
Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]